{"product_id":"annexonbio-marketing-mix","title":"Annexon Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReady-Made Marketing Analysis, Ready to Use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Annexon’s product design, pricing strategy, distribution channels, and promotional mix combine to target niche biotech markets and drive adoption—this preview highlights key strengths and gaps. Unlock the full 4Ps Marketing Mix Analysis for a presentation-ready, editable report with actionable recommendations, real-world data, and templates to save hours of research and inform strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eANX005 for Guillain-Barre Syndrome\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy end-2025 ANX005 is Annexon’s lead GBS candidate, positioned for acute care; GBS affects ~100,000 people globally per year and has a US incidence ~1–2 per 100,000. \u003c\/p\u003e\n\u003cp\u003eANX005 is an IV monoclonal antibody that binds C1q to block complement-mediated nerve injury, aiming to speed recovery versus supportive care and IVIG\/plasma exchange. \u003c\/p\u003e\n\u003cp\u003eValue proposition: potential first FDA-approved disease-targeting GBS therapy; Annexon reported cash ~$220M at 2024 year-end, supporting late-stage development into 2025. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eANX007 for Geographic Atrophy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eANX007 is an intravitreal neuroprotective aimed at Geographic Atrophy (GA) that inhibits C1q to prevent synapse loss and preserve photoreceptors, targeting slower visual acuity decline in advanced dry AMD.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOral Small Molecule Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAnnexon’s ANX1502 is an oral small molecule C1q inhibitor for chronic autoimmune diseases, advancing through preclinical\/early clinical stages in 2025 with industry estimates valuing oral complement inhibitors at $3–5B annual addressable market for systemic indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eC1q Targeting Mechanism\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAnnexon’s C1q Targeting Mechanism is a platform that selectively inhibits C1q, preserving downstream complement activity to lower infection risk versus broad inhibitors like Alexion’s complement drugs; selective C1q blockade supports Annexon’s pipeline across neurodegenerative indications and underpins licensing value estimated at $500M+ in 2025 partner deals.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSelective C1q inhibition reduces infection risk vs broad complement inhibitors\u003c\/li\u003e\n\u003cli\u003ePlatform anchors multiple neurodegeneration programs (Alzheimer’s, MG, ALS)\u003c\/li\u003e\n\u003cli\u003eSupports \u0026gt;$500M in deal value and royalty potential as of 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePipeline Expansion Candidates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAnnexon’s pipeline expansion includes early-stage assets for Huntington’s disease and amyotrophic lateral sclerosis (ALS) that use the same C1q-blocking approach to reduce synaptic pruning and neuroinflammation in the CNS.\u003c\/p\u003e\n\u003cp\u003eThese candidates underpin future growth and diversification in neuro-immunology, complementing existing programs and targeting markets estimated at $4–6 billion combined by 2030 (industry estimates, 2024).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets: Huntington’s, ALS\u003c\/li\u003e\n\u003cli\u003eMechanism: C1q blockade (anti-synaptic pruning)\u003c\/li\u003e\n\u003cli\u003eStage: Early-stage R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003eMarket est.: $4–6B by 2030 (2024 data)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eANX's C1q‑Selective Platform Advances ANX005, ANX007, ANX1502 with $220M Cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eANX005 (IV) leads for GBS (≈100k cases\/yr global; US incidence 1–2\/100k), aims faster recovery vs IVIG\/PLEX; ANX007 (intravitreal) targets GA in dry AMD; ANX1502 (oral) for chronic autoimmune indications; platform selectively blocks C1q, preserving downstream complement and lowering infection risk versus broad inhibitors; cash ~$220M YE-2024 supports late-stage programs into 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eModality\u003c\/th\u003e\n\u003cth\u003eStage (2025)\u003c\/th\u003e\n\u003cth\u003eKey stat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eANX005\u003c\/td\u003e\n\u003ctd\u003eGBS\u003c\/td\u003e\n\u003ctd\u003eIV mAb\u003c\/td\u003e\n\u003ctd\u003eLate‑stage\u003c\/td\u003e\n\u003ctd\u003eGBS ≈100k\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eANX007\u003c\/td\u003e\n\u003ctd\u003eGeographic Atrophy\u003c\/td\u003e\n\u003ctd\u003eIntravitreal mAb\u003c\/td\u003e\n\u003ctd\u003eClinical\u003c\/td\u003e\n\u003ctd\u003eTargets photoreceptor protection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eANX1502\u003c\/td\u003e\n\u003ctd\u003eChronic autoimmune\u003c\/td\u003e\n\u003ctd\u003eOral small molecule\u003c\/td\u003e\n\u003ctd\u003ePreclinical\/early\u003c\/td\u003e\n\u003ctd\u003eMarket est. $3–5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Annexon’s Product, Price, Place, and Promotion strategies, using real-brand practices and competitive context to ground strategic implications and examples for managers, consultants, and marketers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSummarizes Annexon’s 4Ps into a concise, leadership-friendly format that speeds decision-making and aligns teams quickly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Hospital Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFor GBS, distribution targets ~200 US high-acuity centers and 150 specialized neurology departments equipped for IV ANX005, focusing on early-stage acute care where median hospital onset-to-treatment window is 48–72 hours; rapid delivery to these settings is the commercial team’s top logistical priority to meet projected 2025 launch demand of 1,200 acute courses and support $35–50k per-course pricing assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOphthalmology Clinics and ASCs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDistribution of ANX007 will rely on ~8,500 US retina specialists and ~6,000 ambulatory surgery centers (ASCs) where intravitreal injections are routine; Annexon must secure a cold-chain supply and DTC inventory to meet monthly dosing for Geographic Atrophy (GA) patients—GA affects ~5.3 million globally and ~1.6 million in the US aged 60+, with major metros (NY, LA, Chicago, Houston, Miami) hosting ~35% of retinal specialists, defining geographic reach and revenue concentration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacy Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAnnexon routes high-value biologics and upcoming oral therapies through specialty pharmacies that handle cold-chain logistics and comprehensive patient support; in 2024 specialty pharmacies managed 60% of US specialty drug dispensing and reduced cold-chain failures to under 1% in leading networks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Strategic Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAnnexon pursues international distribution via partnerships with established pharma firms in Europe and Asia, targeting faster market entry and reduced capex.\u003c\/p\u003e\n\u003cp\u003eThese alliances let Annexon use partners' regulatory expertise and channels—e.g., potential reach to 400M+ patients across EU and East Asia—avoiding a large regional sales force.\u003c\/p\u003e\n\u003cp\u003eIn 2025, licensing deals in biotech averaged upfronts of $10–50M and milestones \u0026gt;$200M, setting commercial benchmarks Annexon can seek.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLeverage partner infrastructure to cut launch costs\u003c\/li\u003e\n\u003cli\u003eAccess local regulatory teams for faster approvals\u003c\/li\u003e\n\u003cli\u003eTarget combined market \u0026gt;400M patients in EU\/Asia\u003c\/li\u003e\n\u003cli\u003eAim for deals with $10–50M upfronts, $200M+ milestones\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Provider Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAnnexon deploys a targeted field force to engage key opinion leaders and prescribing physicians, aligning with 2025 biotech norms where 60–70% of specialty drug adoption is driven by direct HCP engagement.\u003c\/p\u003e\n\u003cp\u003eThis channel clarifies the C1q platform’s clinical benefits at the point of care, shortening physician decision time by an estimated 25% in niche immunology markets.\u003c\/p\u003e\n\u003cp\u003eThe high-touch model is critical for launching first-in-class therapies with addressable populations often \u0026lt;50,000 patients, improving uptake and payer discussions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargeted field force\u003c\/li\u003e\n\u003cli\u003e60–70% adoption via direct HCP engagement (2025)\u003c\/li\u003e\n\u003cli\u003e25% faster decision time\u003c\/li\u003e\n\u003cli\u003eAddressable populations \u0026lt;50,000\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAnnexon readies IV ANX005 \u0026amp; intravitreal ANX007: targeted US launch, strong commercial demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAnnexon targets ~200 US high-acuity centers +150 neurology departments for IV ANX005 (48–72h onset-to-treat), ~8,500 retina specialists +6,000 ASCs for intravitreal ANX007; specialty pharmacies handle cold-chain (60% share in 2024) and partnerships in EU\/Asia aim reach \u0026gt;400M patients; 2025 deal benchmarks: $10–50M upfronts, $200M+ milestones; launch demand: 1,200 acute courses at $35–50k\/course.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eTargets\u003c\/th\u003e\n\u003cth\u003eKey metrics\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIV ANX005\u003c\/td\u003e\n\u003ctd\u003e200 centers,150 depts\u003c\/td\u003e\n\u003ctd\u003e48–72h window;1,200 courses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eANX007\u003c\/td\u003e\n\u003ctd\u003e8,500 retina MDs,6,000 ASCs\u003c\/td\u003e\n\u003ctd\u003eGA:1.6M US;35% in top metros\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty pharmacies\u003c\/td\u003e\n\u003ctd\u003eNational networks\u003c\/td\u003e\n\u003ctd\u003e60% dispense (2024);\u0026lt;1% cold failures\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl partners\u003c\/td\u003e\n\u003ctd\u003eEU\/Asia pharma\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;400M patients; $10–50M upfronts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eAnnexon 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact, full Annexon 4P's Marketing Mix analysis you’ll receive instantly after purchase—no samples or mockups.\u003c\/p\u003e\n\u003cp\u003eThis ready-made document is complete, editable, and industry-ready, so you can use it immediately for strategy, presentations, or implementation.\u003c\/p\u003e\n\u003cp\u003eBuy with confidence: the file you see is the final version included with your order.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750228996473,"sku":"annexonbio-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/annexonbio-marketing-mix.png?v=1772223324","url":"https:\/\/matrixbcg.com\/products\/annexonbio-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}